Daewoong completes combination therapy of antidiabetic drug Enavogliflozin

Confirmed positive phase 3 topline results in addition to Enavogliflozin monotherapy and Metformin combination therapy

Alkem Labs to launch treatment for Diabetic Foot Ulcer

This advanced technology for Diabetic Foot Ulcer (DFU), management has a high scope of preventing amputations in diabetic patients. It has no definitive treatment in India. This technology will be available at affordable rates

Network18 Group and Novartis India launch ‘Netra Suraksha’ to raise awareness around diabetic eye diseases

The aim is to create an awareness programme that will drive diabetic patients to get their eyes tested regularly

NPPA fixes ceiling price for anti-diabetic generic medicines

A total of 12 generic medicines have been included in the list

QMS Medical partners with ZEISS for screening diabetic retinopathy

Remote screening of diabetic retinopathy can help in early detection, even before there are any noticeable vision changes

Aarti Drugs posts Q1 FY26 PAT higher at Rs. 54 Cr

During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D

Biocon Biologics expands diabetes portfolio with FDA approval of Kirsty

European Commission approves Eylea 8 mg with extended 6-month treatment interval for nAMD and visual impairment due to DME

Eylea 8 mg is the first and only anti-vascular endothelial growth factor (VEGF) treatment in the EU with treatment intervals of up to 6 months for both patients with nAMD and DME

Biocon Biologics receives Health Canada approval for Yesafili

The approval is based on a comprehensive package of analytical, nonclinical, and clinical data

NPPA fixes retail prices for 41 drug combinations

The NPPA has capped prices for 41 drug combinations including diabetes, cholesterol, and sleep disorder treatments